Literature DB >> 9613522

Treatment of brain tumors in children is associated with abnormal MR spectroscopic ratios in brain tissue remote from the tumor site.

S M Waldrop1, P C Davis, C A Padgett, M B Shapiro, R Morris.   

Abstract

PURPOSE: Children who have brain tumors are at risk for a variety of treatment-related sequelae, including neuropsychological and cognitive impairment, neurologic deficits, and neuroendocrinologic disturbances. We sought to determine the value of proton MR spectroscopy in assessing brain tissue remote from the tumor site to ascertain the effects of chemotherapy and radiation treatment in these patients.
METHODS: Single-voxel proton MR spectra from 70 patients (111 spectra) and 11 healthy volunteers (11 spectra) were analyzed. NAA/Cr, NAA/Cho, and Cho/Cr ratios based on peak areas were obtained from nonneoplastic regions of the frontal lobe. The relationship between MR spectroscopic ratios and treatment was determined.
RESULTS: NAA-containing ratios were decreased in patients as compared with control subjects. The presence of gadolinium-based contrast material did not cause significant changes in the ratios as compared with precontrast data. When chemotherapy was a component of a child's treatment protocol, we found a significant decline in NAA/Cr ratios. Patients who underwent both chemotherapy and radiation therapy showed a trend toward lower NAA-containing ratios if the chemotherapy was administered before the radiation therapy. Patients receiving whole-brain radiation had a trend toward lower NAA-containing ratios than did those who had only focal tumor treatment.
CONCLUSION: In children with brain tumors, MR spectroscopy of brain tissue remote from the tumor reveals treatment-related biochemical changes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9613522      PMCID: PMC8337588     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  7 in total

Review 1.  Imaging for assessment of radiation-induced normal tissue effects.

Authors:  Robert Jeraj; Yue Cao; Randall K Ten Haken; Carol Hahn; Lawrence Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

2.  201Thallium SPECT and 1H-MRS compared with MRI in chemotherapy monitoring of high-grade malignant astrocytomas.

Authors:  K Kallén; I M Burtscher; S Holtås; E Ryding; I Rosén
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

3.  A pilot study of an online cognitive rehabilitation program for executive function skills in children with cancer-related brain injury.

Authors:  Shelli R Kesler; Norman J Lacayo; Booil Jo
Journal:  Brain Inj       Date:  2011       Impact factor: 2.311

4.  Assessing neurotoxicity from the low-dose radiation component of radiosurgery using magnetic resonance spectroscopy.

Authors:  Chris R Kelsey; Srinivasan Mukundan; Zhiheng Wang; Carol A Hahn; Brian J Soher; John P Kirkpatrick
Journal:  Neuro Oncol       Date:  2010-01-25       Impact factor: 12.300

5.  Prospective serial proton MR spectroscopic assessment of response to tamoxifen for recurrent malignant glioma.

Authors:  Tejas Sankar; Zografos Caramanos; Rachid Assina; Jean-Guy Villemure; Richard Leblanc; Adrian Langleben; Douglas L Arnold; Mark C Preul
Journal:  J Neurooncol       Date:  2008-07-04       Impact factor: 4.130

Review 6.  A systematic review on the use of quantitative imaging to detect cancer therapy adverse effects in normal-appearing brain tissue.

Authors:  Jan Petr; Louise Hogeboom; Pavel Nikulin; Evita Wiegers; Gwen Schroyen; Jesper Kallehauge; Marek Chmelík; Patricia Clement; Ruben E Nechifor; Liviu-Andrei Fodor; Philip C De Witt Hamer; Frederik Barkhof; Cyril Pernet; Maarten Lequin; Sabine Deprez; Radim Jančálek; Henk J M M Mutsaerts; Francesca B Pizzini; Kyrre E Emblem; Vera C Keil
Journal:  MAGMA       Date:  2021-12-17       Impact factor: 2.310

Review 7.  MR Image Changes of Normal-Appearing Brain Tissue after Radiotherapy.

Authors:  Katharina Witzmann; Felix Raschke; Esther G C Troost
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.